These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 32917359

  • 1. Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
    van Geffen WH, Carpaij OA, Westbroek LF, Seigers D, Niemeijer A, Vonk JM, Kerstjens HAM.
    Respir Med; 2020 Sep; 171():106064. PubMed ID: 32917359
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
    Watz H, Mailänder C, Baier M, Kirsten A.
    BMC Pulm Med; 2016 Jun 14; 16(1):95. PubMed ID: 27301417
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct 14; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.
    Norris V, Ambery C.
    Pulm Pharmacol Ther; 2013 Oct 14; 26(5):574-80. PubMed ID: 23524017
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
    Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B.
    Respir Med; 2014 Dec 14; 108(12):1786-93. PubMed ID: 25307414
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P, Hagedorn-Peinz I.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 14; 13():69-77. PubMed ID: 29317812
    [Abstract] [Full Text] [Related]

  • 12. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec 14; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D.
    Lancet; 2018 Mar 17; 391(10125):1076-1084. PubMed ID: 29429593
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.
    Lehmann S, Ringbæk T, Løkke A, Grote L, Hedner J, Lindberg E.
    Int J Chron Obstruct Pulmon Dis; 2019 Mar 17; 14():199-210. PubMed ID: 30666100
    [Abstract] [Full Text] [Related]

  • 16. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
    Kerwin EM, Spangenthal S, Kollar C, St Rose E, Reisner C.
    Respir Res; 2018 Mar 05; 19(1):38. PubMed ID: 29506504
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
    Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV, FLASH Investigators.
    Respirology; 2018 Dec 05; 23(12):1152-1159. PubMed ID: 30074294
    [Abstract] [Full Text] [Related]

  • 18. Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
    Salomon J, Stolz D, Domenighetti G, Frey JG, Turk AJ, Azzola A, Sigrist T, Fitting JW, Schmidt U, Geiser T, Wild C, Kostikas K, Clemens A, Brutsche M.
    Respir Res; 2017 Jan 11; 18(1):13. PubMed ID: 28077140
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D.
    Pulm Pharmacol Ther; 2018 Feb 11; 48():71-79. PubMed ID: 28987804
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.